EN
TR
-
Abstract
Aim. Plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor. It inhibits tissue plasminogen activator (tPA) and urokinase (uPA), and consequently inhibits fibrinolysis. There is a common polymorphism known as 4G/5G in the promoter region of PAI-1 gene. PAI-1 4G/4G polymorphism may contribute pregnancy complications because of its role in thrombosis,. In this study, we aimed to evaluate the possible effect of PAI-1 4G/4G polymorphism to miscarriages. Method. The study group was selected between individuals residing in Sivas region. One hundred and seventy eight women (92 of them have miscarriage story and 86 control) were incorporated to study. After DNA isolation, mutation analysis was performed by StripAssay technique based on the reverse-hybridization principle. Data were analysed by SPSS 15.0 statistic program. Results. In control group, the number of 5G/5G polymorphisms was 22 (25.6%), the number of 4G/5G polymorphisms was 53 (61.6%) and the number of 4G/4G mutant cases was 11 (12.8%). In miscarriage group, the number of 5G/5G polymorphisms was 20 (21.7%), the number of 4G/5G polymorphisms was 49 (53.3%) and the number of 4G/4G mutant cases was 23 (25%). ODDS ratio was calculated for 4G/4G homozygot mutant cases. Conclusion. According to our datas, 5G/5G and 4G/5G polymorphism have not higher risk for miscarriage (p=0.546 and p=0.259 p>0.05). In our study, it was detected that the contribution of 4G/4G polymorphism to miscarriage is important. The women who have this polymorphism carry the risk of miscarriage higher 2.27 fold (p=0.038 p<0.05).
Keywords
Kaynakça
- Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992: 355; 270-3.
- Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D FerrieresJ, Evans A, Amouyel P, Poirier O, Cambien F, Vague IJ. Five frequent polymorphisms of the PAI-1 gene lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arteriosclerosis, Thrombosis, and Vascular Biology 1997; 17: 851-8.
- Magdoud K, Herbepin VG, Touraine R, Almawi WY, Mahjoub T. Plasminogen activator inhibitor 1 4G/5G and 844G/A variants in idiopathic recurrent pregnancy loss. American Journal of Reproductive Immunology 2013; 246-52.
- Juhan-Vague I, Alessi MC. PAI-1, Obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-60.
- Attia J, Thakkinstian A, Wang Y, Lincz L, Parsons M, Sturm J, McGettigan P, Scott R, Meldrum C, Levi C. The PAI-1 4G/5G gene polymorphism and ischemic stroke: An association study and meta-analysis. J Stroke Cerebrovasc Dis 2007; 16: 173-9.
- Su S, Chen S, Zhao J, Huang J, Wang X, Chen R, Gu D. Plasminogen activator inhibitor-1 gene selection of tagging single nucleotide polymorphisms and association with coronary heart disease.. Arteriosclerosis Thrombosis and Vascular Biology 2006; 26: 948-54.
- MargaglioneM, Cappucci G, Colaizzo D, Giuliani N Vecchione G, Grandone E, Pennelli O, Di Minno G. The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family history of coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 1998; 18: 152-6.
- Abboud N, Ghazouani L, Saidi S, Ben-Hadj-Khalifa S, Addad F, Almawi WY, Mahjoub T. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1 /tissue plasminogen activator levels in myocardial infarction: A case-control study. Genet Test Mol Biomarkers 2010; 14: 23-7.
Ayrıntılar
Birincil Dil
Türkçe
Konular
-
Bölüm
-
Yayımlanma Tarihi
7 Ağustos 2014
Gönderilme Tarihi
7 Ağustos 2014
Kabul Tarihi
-
Yayımlandığı Sayı
Yıl 1970 Cilt: 36 Sayı: 3
AMA
1.Yıldırım M, Dağ Ş, Kurtulgan H, Karakuş S. Plazminojen aktivatör inhibitor-1 (PAI-1) 4g/4g polimorfizminin gebelik kayıplarıyla ilişkisi. CMJ. 2014;36(3):350-355. doi:10.7197/cmj.v36i3.5000060803